Related references
Note: Only part of the references are listed.Chemotherapy vs. allogeneic transplantation as post molecular remission therapy in patients aged less than 60 years with Philadelphia-positive ALL
Libing Wang et al.
BONE MARROW TRANSPLANTATION (2020)
A High-Sensitivity 10-Color Flow Cytometric Minimal Residual Disease Assay in B-Lymphoblastic Leukemia/Lymphoma Can Easily Achieve the Sensitivity of 2-in-106 and Is Superior to Standard Minimal Residual Disease Assay: A Study of 622 PatientsKey terms
Prashant R. Tembhare et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2020)
Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study
Hagop M. Kantarjian et al.
CANCER (2019)
A systematic literature review and meta-analysis of minimal residual disease as a prognostic indicator in adult B-cell acute lymphoblastic leukemia
Renato Bassan et al.
HAEMATOLOGICA (2019)
Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph plus ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1
H. Pfeifer et al.
LEUKEMIA (2019)
ClonoSEQ assay for the detection of lymphoid malignancies
Anna Monter et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2019)
Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study
Monika Brueggemann et al.
LEUKEMIA (2019)
Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study
Elias J. Jabbour et al.
CANCER (2019)
Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts
Nicholas J. Short et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Allogeneic Hematopoietic Stem Cell Transplantation, Especially Haploidentical, May Improve Long-Term Survival for High-Risk Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Tyrosine Kinase Inhibitor Era
Yu-juan Xue et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Next-generation antigen receptor sequencing of paired diagnosis and relapse samples of B-cell acute lymphoblastic leukemia: Clonal evolution and implications for minimal residual disease target selection
Prisca M. J. Theunissen et al.
LEUKEMIA RESEARCH (2019)
Minimal residual disease status determined by multiparametric flow cytometry pretransplantation predicts the outcome of patients with ALL receiving unmanipulated haploidentical allografts
Xiao-Su Zhao et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia
Nicola Goekbuget et al.
HEMATOLOGY (2019)
Combination of IKZF1 deletion and early molecular response show significant roles on prognostic stratification in Philadelphia chromosome-positive acute lymphoblastic leukemia patients
He Li et al.
LEUKEMIA & LYMPHOMA (2018)
Genomic CDKN2A/2B deletions in adult Ph+ ALL are adverse despite allogeneic stem cell transplantation
Heike Pfeifer et al.
BLOOD (2018)
Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia
Nicola Goekbuget et al.
BLOOD (2018)
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
Gerrit J. Schuurhuis et al.
BLOOD (2018)
Efficacy of Ponatinib Versus Earlier Generation Tyrosine Kinase Inhibitors for Front-line Treatment of Newly Diagnosed Philadelphia-positive Acute Lymphoblastic Leukemia
Elias Jabbour et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2018)
Genotype-Specific Minimal Residual Disease Interpretation Improves Stratification in Pediatric Acute Lymphoblastic Leukemia
David O'Connor et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Droplet Digital PCR Is a Robust Tool for Monitoring Minimal Residual Disease in Adult Philadelphia-Positive Acute Lymphoblastic Leukemia
Nicoletta Coccaro et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2018)
Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study
Hagop Kantarjian et al.
LANCET ONCOLOGY (2018)
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Jae H. Park et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Novel Therapies for Older Adults With Acute Lymphoblastic Leukemia
Nicholas J. Short et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2018)
Impact of minimal residual disease (MRD) status in clinical outcomes of patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) treated with inotuzumab ozogamicin (InO) in the phase 3 INO-VATE trial.
Elias Jabbour et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
HEALTH POLICY Eliminating MRD - FDA approval of blinatumomab for B-ALL in complete remission
Talal Hilal et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study
Elias Jabbour et al.
LANCET HAEMATOLOGY (2018)
A Phase II Study of the Hyper-CVAD Regimen in Sequential Combination with Blinatumomab As Frontline Therapy for Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Guillaume Richard-Carpentier et al.
BLOOD (2018)
Results of SWOG 1318: A Phase 2 Trial of Blinatumomab Followed By Pomp (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) Maintenance in Elderly Patients with Newly Diagnosed Philadelphia Chromosome Negative B-Cell Acute Lymphoblastic Leukemia
Anjali S. Advani et al.
BLOOD (2018)
Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL
Brent Wood et al.
BLOOD (2018)
Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia
Prisca Theunissen et al.
BLOOD (2017)
Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease
Ghayas C. Issa et al.
CANCER (2017)
Differential Impact of Minimal Residual Disease Negativity According to the Salvage Status in Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
Elias Jabbour et al.
CANCER (2017)
Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Mar row Transplantation
Sebastian Giebel et al.
HAEMATOLOGICA (2017)
Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Mar row Transplantation
Sebastian Giebel et al.
HAEMATOLOGICA (2017)
Antigen receptor sequencing of paired bone marrow samples shows homogeneous distribution of acute lymphoblastic leukemia subclones
Prisca M. J. Theunissen et al.
HAEMATOLOGICA (2017)
Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study
Giovanni Martinelli et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Minimal Residual Disease in Acute Lymphoblastic Leukemia: How to Recognize and Treat It
Nicholas J. Short et al.
CURRENT ONCOLOGY REPORTS (2017)
Antigen receptor sequencing of paired bone marrow samples shows homogeneous distribution of acute lymphoblastic leukemia subclones
Prisca M. J. Theunissen et al.
HAEMATOLOGICA (2017)
Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia AMeta-analysis
Donald A. Berry et al.
JAMA ONCOLOGY (2017)
Which tyrosine kinase inhibitor should we use to treat Philadelphia chromosome-positive acute lymphoblastic leukemia?
Nicholas J. Short et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2017)
How do we measure MRD in ALL and how should measurements affect decisions. Re: Treatment and prognosis?
Xueyan Chen et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2017)
Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission
Naveen Pemmaraju et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Next-Generation Sequencing in Adult B Cell Acute Lymphoblastic Leukemia Patients
Olga Sala Torra et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)
Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia
Farhad Ravandi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Principles of Minimal Residual Disease Detection for Hematopoietic Neoplasms by Flow Cytometry
Brent L. Wood
CYTOMETRY PART B-CLINICAL CYTOMETRY (2016)
Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
Nicholas J. Short et al.
BLOOD (2016)
Use of Tyrosine Kinase Inhibitors to Prevent Relapse After Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Position Statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Sebastian Gebel et al.
CANCER (2016)
Hyper-CVAD Plus Ponatinib Versus Hyper-CVAD Plus Dasatinib as Frontline Therapy for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Propensity Score Analysis
Koji Sasaki et al.
CANCER (2016)
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
Hagop M. Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
B-ALL Minimal Residual Disease Flow Cytometry An Application of a Novel Method for Optimization of a Single-Tube Model
Aaron C. Shaver et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2015)
Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies
Jacques J. M. van Dongen et al.
BLOOD (2015)
Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia
Nathalie Dhedin et al.
BLOOD (2015)
Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment
Gerhard Zugmaier et al.
BLOOD (2015)
Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia
Rosemary Sutton et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Immunoglobulin and T Cell Receptor Gene High-Throughput Sequencing Quantifies Minimal Residual Disease in Acute Lymphoblastic Leukemia and Predicts Post-Transplantation Relapse and Survival
Aaron C. Logan et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia
Kheira Beldjord et al.
BLOOD (2014)
Drug Resistance and BCR-ABL Kinase Domain Mutations in Philadelphia Chromosome- Positive Acute Lymphoblastic Leukemia From the Imatinib to the Second- Generation Tyrosine Kinase Inhibitor Era
Simona Soverini et al.
CANCER (2014)
Detection of Minimal Residual Disease in B Lymphoblastic Leukemia by High-Throughput Sequencing of IGH
David Wu et al.
CLINICAL CANCER RESEARCH (2014)
Treatment of High-Risk Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in Adolescents and Adults According to Early Cytologic Response and Minimal Residual Disease After Consolidation Assessed by Flow Cytometry: Final Results of the PETHEMA ALL-AR-03 Trial
Josep-Maria Ribera et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders
M. Ladetto et al.
LEUKEMIA (2014)
Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy
Farhad Ravandi et al.
BLOOD (2013)
Quantification of minimal residual disease levels by flow cytometry at time of transplant predicts outcome after myeloablative allogeneic transplantation in ALL
J. Sanchez-Garcia et al.
BONE MARROW TRANSPLANTATION (2013)
Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial
Ajay Vora et al.
LANCET ONCOLOGY (2013)
Monitoring MRD with flow cytometry: an effective method to predict relapse for ALL patients after allogeneic hematopoietic stem cell transplantation
Xiao-Su Zhao et al.
ANNALS OF HEMATOLOGY (2012)
Unrelated Cord Blood Transplantation in Adult and Pediatric Acute Lymphoblastic Leukemia: Effect of Minimal Residual Disease on Relapse and Survival
Veronika Bachanova et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2012)
Has MRD monitoring superseded other prognostic factors in adult ALL?
Monika Brueggemann et al.
BLOOD (2012)
Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL
Max S. Topp et al.
BLOOD (2012)
Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies
Nicola Goekbuget et al.
BLOOD (2012)
Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia
Malek Faham et al.
BLOOD (2012)
Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial
Jonathan I. Sive et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Time point-dependent concordance of flow cytometry and real-time quantitative polymerase chain reaction for minimal residual disease detection in childhood acute lymphoblastic leukemia
Giuseppe Gaipa et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
High-Throughput Sequencing Detects Minimal Residual Disease in Acute T Lymphoblastic Leukemia
David Wu et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Minimal residual disease assessment in childhood acute lymphoblastic leukaemia: a Swedish multi-centre study comparing real-time polymerase chain reaction and multicolour flow cytometry
Ingrid Thorn et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Targeted Therapy With the T-Cell-Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival
Max S. Topp et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)
Renato Bassan et al.
BLOOD (2009)
Minimal residual disease detection in childhood acute lymphoblastic leukaemia patients at multiple time-points reveals high levels of concordance between molecular and immunophenotypic approaches
Jacqueline Ryan et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Prognostic Value of Minimal Residual Disease Quantification Before Allogeneic Stem-Cell Transplantation in Relapsed Childhood Acute Lymphoblastic Leukemia: The ALL-REZ BFM Study Group
Peter Bader et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study
Michael J. Borowitz et al.
BLOOD (2008)
Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia.: The Polish Adult Leukemia Group ALL 4-2002 MRD Study
Jerzy Holowiecki et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Results of the Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone Regimen in Elderly Patients With Acute Lymphocytic Leukemia
Susan O'Brien et al.
CANCER (2008)
Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia
Orietta Spinelli et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2007)
Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment:: data from the GMALL 06/99 and 07/03 trials
Thorsten Raff et al.
BLOOD (2007)
Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data
V. H. J. van der Velden et al.
LEUKEMIA (2007)
Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia
M Brüggemann et al.
BLOOD (2006)
Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia
H Kantarjian et al.
CANCER (2004)
Analysis of minimal residual disease in childhood acute lymphoblastic leukemia:: comparison between RQ-PCR analysis of Ig/TcR gene rearrangements and multicolor flow cytometric immunophenotyping
M Malec et al.
LEUKEMIA (2004)
Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias:: early immunophenotypic evaluation has high clinical value
MB Vidriales et al.
BLOOD (2003)
Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia
FY Mortuza et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Clinical value of immunological monitoring of minimal residual disease in acute lymphoblastic leukaemia after allogeneic transplantation
J Sanchez et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
Share Paper
